La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Solesence a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Solesence..

Solesence (OTC:NANX) Azioni, Catena delle Opzioni

Nanophase Technologies

Nanophase Technologies Corp (now Solesence, Inc) provides scientifically-driven health care solutions across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The company focuses on skin health through its consumer products and Active Pharmaceutical Ingredients (APIs). It produces materials for use in personal care products, including ingredients for use in sunscreens as active pharmaceutical ingredients (APIs); and also develops skin care, sun care, and color cosmetics products and offers them for sale to brands that ultimately sell products to consumers. Geographically, the company operates in the United States.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

CYAN

NANX

RRGB

Scopri le 4 penny stock sotto $5 che stanno attirando l&#39;attenzione degli insider e valutane il potenziale di crescita.

4 penny stock sotto $5 che gli insider stanno acquistando

NANOPHASE TECHS CORP by Nanophase Technologies Corp.

Solesence Inc

ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) -- Sol&eacute;sence, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTCQB">NANX</a>), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to transfer its listing to the Nasdaq Capital Market. The Company&#39;s securities will be uplisted to Nasdaq at the opening of business on Tuesday, April 8, 2025. Prior to listing on Nasdaq, the Company&#39;s shares traded on the OTCQB. Shareholders are not required to take any action as a result of the uplisting.
The Company&#39;s shares will now trade under the ticker symbol &quot;SLSN&quot;. The approval by Nasdaq was based on the Company meeting all applicable requirements for public listing on the Nasdaq Capital Market.
&quot;We are pleased to announce our uplisting to Nasdaq,&quot; said Jess Jankowski, President and Chief Executive Officer of Sol&eacute;sence. &quot;Sol&eacute;sence continues to redefine mineral-based sun protection as beauty brands recognize the novel skin health benefits from our award-winning products. We believe that trading on Nasdaq will increase our visibility within the investment community, broaden our shareholder base, and deliver greater value to our stakeholders. We look forward to this exciting new chapter in our company&#39;s history.&quot;
&quot;This milestone was achieved through our team&#39;s relentless efforts to profitably achieve our mission, our brand partners&#39; collaboration in driving growth at a multiple of the industry&#39;s growth rate, and the patience and resilience of our shareholders. We&#39;re particularly excited about how Sol&eacute;sence&#39;s uplisting to Nasdaq may one day provide resources to enable our company to scale and increase profitability in a manner not available to most of our competitors,&quot; said Kevin Cureton, Chief Operating Officer.

SLSN

Solésence Announces Uplisting To Nasdaq

Nanophase Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) reported quarterly earnings of $0.04 per share. This is a 233.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported $16.87 million in sales this quarter. This is a 111.94 percent increase over sales of $7.96 million the same period last year.

Earnings

Nanophase Technologies Q3 GAAP EPS $0.04 Up From $(0.03) YoY, Sales $16.87M Up From $7.96M YoY

The Dow Jones index closed higher by more than 1% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Roadzen</h3>
<ul>
<li>The Trade: Roadzen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) Rohan Malhotra <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 2,600 shares</a> at an average price of &nbsp;&nbsp; $1.92. To acquire these shares, it cost around $4,999.</li>
<li>What's Happening: On Aug. 13, Roadzen reported a quarterly loss of 71 cents per share.</li>
<li>What Roadzen Does: Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI.</li>
</ul>
<h3 class="wp-block-heading">System1</h3>
<ul>
<li>The Trade: System1, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) 10% owner Cee Holdings Trust <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 18,055 shares</a> at an average price of $1.22. To acquire these shares, it cost around $21,961.</li>
<li>What's Happening: On Aug. 8, System1 posted upbeat quarterly earnings.</li>
<li>What System1 Does: System1 Inc develops technology and data science to operate a responsive acquisition marketing platform.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) R Janet Whitmore Gaboury <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,488 shares</a> at an average price of $1.51. The insider spent around $6,777 to buy those shares.</li>
<li>What's Happening: On Aug. 6, Nanophase Technologies posted an increase in second-quarter sales.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy..</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40785814/dow-jumps-over-1-following-last-weeks-selloff-investor-sentiment-improves-but-fear-greed-index-rema">Dow Jumps Over 1% Following Last Week&#8217;s Selloff: Investor Sentiment Improves, But Fear &amp; Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

RDZN

System1 And 2 Other Stocks Under $2 Executives Are Buying

The Dow Jones index closed lower by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Cyanotech</h3>
<ul>
<li>The Trade: Cyanotech Corporation (OTC:: CYAN) Director Michael A / Davis <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 47,037 shares</a> at an average price of $0.82. To acquire these shares, it cost around $8,200.</li>
<li>What's Happening: On Aug. 7, Cyanotech announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024.</li>
<li>What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.</li>
</ul>
<h3 class="wp-block-heading">Emeren Group</h3>
<ul>
<li>The Trade: Emeren Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) 10% owner Shah Capital Management<a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 70,194 shares</a> at an average price of $1.84. To acquire these shares, it cost around $129,322.</li>
<li>What's Happening: On Sept. 3, Emeren named Dr. Ramki Srinivasan to its Board of Directors.</li>
<li>What Emeren Group Does: Emeren Group Ltd is a solar project developer and operator, a solar downstream player.</li>
</ul>
<h3 class="wp-block-heading">Red Robin Gourmet Burgers</h3>
<ul>
<li>The Trade: Red Robin Gourmet Burgers, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) CFO Joshua Todd Wilson <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $3.60. The insider spent around $18,000 to buy those shares.</li>
<li>What's Happening: On Aug. 22, Red Robin reported downbeat earnings for its second quarter and lowered its FY24 revenue guidance.</li>
<li>What Red Robin Does: Red Robin Gourmet Burgers Inc is a restaurant operator.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/quote/NANX/analyst-ratings">acquired a total of 9,263 shares</a> at an average price of $1.50. The insider spent around $13,889 to buy those shares.</li>
<li>What's Happening: On Aug. 6, Nanophase Technologies posted an increase in second-quarter sales.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

Red Robin And 3 Other Stocks Under $5 Executives Are Buying

The Dow Jones index closed lower by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 21,040 shares</a> at an average price of $1.59. To acquire these shares, it cost around $33,454.</li>
<li>What's Happening: On Aug. 6, Nanophase Technologies posted an increase in second-quarter sales.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3 class="wp-block-heading">Alset</h3>
<ul>
<li>The Trade: Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) CEO Heng Fai Ambrose Chan <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,983 shares at</a> an average price of $0.95. To acquire these shares, it cost around $2,834.</li>
<li>What's Happening: The company's stock gained around 39% over the past five days.</li>
<li>What Alset Does: Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea.</li>
</ul>
<h3 class="wp-block-heading">CPI Aerostructures</h3>
<ul>
<li>The Trade: CPI Aerostructures, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVU#NYSE">CVU</a>) Director Richard S Caswell <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,000 shares</a> at an average price of $2.69. The insider spent around $13,450 to buy those shares.</li>
<li>What's Happening: On Aug. 20, CPI Aerostructures named Philip Passarello as CFO.</li>
<li>What CPI Aerostructures Does: CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40521759/intuit-ross-stores-and-3-stocks-to-watch-heading-into-friday">Intuit, Ross Stores And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

CPI Aerostructures And 2 Other Stocks Under $3 Executives Are Buying

Nanophase Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) reported quarterly earnings of $0.01 per share. This is unchanged from the same period last year. The company reported $13.05 million in sales this quarter. This is a 9.89 percent increase over sales of $11.87 million the same period last year.

Nanophase Technologies Q2 EPS $0.01, Same YoY, Sales $13.05M Up From $11.87M YoY

The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NANX#NASDAQ">NANX</a>) Chief Operating Officer Kevin Cureton <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 11,675 shares</a> at an average price of $1.49. To acquire these shares, it cost around $17,414.</li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3 class="wp-block-heading">Nuvation Bio</h3>
<ul>
<li>The Trade: Nuvation Bio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) Director Xiangmin Cui <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 500,000 shares at</a> an average price of $2.98. To acquire these shares, it cost around $1.5 million.</li>
<li>What's Happening: On June 3, HC Wainwright &amp; Co. analyst Robert Burns reiterated Nuvation Bio with a Buy and maintained a price target of $8.</li>
<li>What Nuvation Bio Does: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.</li>
</ul>
<h3 class="wp-block-heading">NeuroBo Pharmaceuticals</h3>
<ul>
<li>The Trade: NeuroBo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) President and CEO Faheem Hasnain <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,544,530 shares</a> at an average price of $3.13. The insider spent around $7.97 million to buy those shares. </li>
<li>What's Happening: On June 25, NeuroBo Pharmaceuticals announced the closing of up to $70 million concurrent private placement and registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>What NeuroBo Pharmaceuticals Does: NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.</li>
</ul>
Read More: <a href="https://www.benzinga.com/24/06/39499222/top-3-materials-stocks-that-may-explode-in-q2">Top 3 Materials Stocks That May Explode In Q2</a>

NRBO

NUVB

NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Kronos Bio</h3>
<ul>
<li>The Trade: Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) President and CEO Norbert W Bischofberger <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 3,005,122 shares</a> at an average price of $1.04. To acquire these shares, it cost around $3.12 million.</li>
<li>What's Happening: On May 21, Kronos Bio named Deborah Knobelman as COO and CFO.</li>
<li>What Kronos Bio Does: Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription.</li>
</ul>
<h3 class="wp-block-heading">Assertio Holdings</h3>
<ul>
<li>The Trade: Assertio Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) Director Jeff L Vacirca <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 10,000 shares at </a>an average price of $1.11. To acquire these shares, it cost around $11,100.</li>
<li>What's Happening: On June 6, Assertio Holdings reported inducement grants under NASDAQ Listing Rule 5635(c)(4).</li>
<li>What Assertio Holdings Does: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 18,369 shares</a> at an average price of $1.44. The insider spent around $26,487 to buy those shares. </li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/top-stories/24/06/39290971/jim-cramer-likes-this-energy-stock-with-4-yield-recommends-buying-draftkings">Jim Cramer Likes This Energy Stock With 4% Yield, Recommends Buying DraftKings</a>

ASRT

KRON

Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Crexendo</h3>
<ul>
<li>The Trade: Crexendo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) Chief Revenue Officer Jon Brinton <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 1,000 shares</a> at an average price of $3.51. To acquire these shares, it cost around $3,510.</li>
<li>What's Happening: On May 7, Crexendo posted upbeat quarterly results.</li>
<li>What Crexendo Does: Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services.</li>
</ul>
<h3 class="wp-block-heading">Retractable Technologies</h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVP#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 32,752 shares</a> at an average price of $0.88. To acquire these shares, it cost around $28,884.</li>
<li>What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39006627/top-3-materials-stocks-that-are-set-to-fly-this-quarter">Top 3 Materials Stocks That Are Set To Fly This Quarter</a>
<h3 class="wp-block-heading">Aurora Innovation</h3>
<ul>
<li>The Trade: Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) 10% owner Uber Technologies, Inc <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 25,037,036 shares</a> at an average price of $3.00. The insider spent around $75 million to buy those shares. </li>
<li>What's Happening: On May 8, Aurora Innovation reported a narrower-than-expected first-quarter loss.</li>
<li>What Aurora Innovation Does: Aurora Innovation Inc is engaged in delivering self-driving technology safely, quickly, and broadly.</li>
</ul>
<h3 class="wp-block-heading">Telos</h3>
<ul>
<li>The Trade: Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) Director Fredrick Schaufeld <a href="https://www.benzinga.com/quote/TLS/analyst-ratings">acquired a total of 54,650 shares</a> at an average price of $3.98. The insider spent around $217,507 to buy those shares.</li>
<li>What's Happening: On May 10, Telos posted upbeat quarterly results.</li>
<li>What Telos Does: Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world&#8217;s security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 19,040 shares</a> at an average price of $1.36. The insider spent $25,962 to buy those shares.</li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Don&#8217;t forget to check out our p<a href="https://www.benzinga.com/premarket/">remarket coverage here</a>

CXDO

$75M Bet On Aurora Innovation? Check Out These 5 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Earth Science Tech</h3>
<ul>
<li>The Trade: Earth Science Tech, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ETST#OTC">ETST</a>) Director Yovan Arturo Sanchez <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,500 shares</a> at an average price of $0.10. To acquire these shares, it cost around $1,050.</li>
<li>What's Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.</li>
<li>What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.</li>
</ul>
<h3 class="wp-block-heading">Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 5,300 shares at</a> an average price of $1.40. To acquire these shares, it cost around $7,420.</li>
<li>What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3 class="wp-block-heading">Cerus</h3>
<ul>
<li>The Trade: Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) Director Jami K Nachtsheim <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 2,000 shares</a> at an average price of $1.79. The insider spent around $3,578 to buy those shares.</li>
<li>What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.</li>
<li>What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.</li>
</ul>
<h3 class="wp-block-heading">Zomedica</h3>
<ul>
<li>The Trade: Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) CEO Larry C Heaton II <a href="https://www.benzinga.com/quote/RVP/analyst-ratings">acquired a total of 100,000 shares</a> at an average price of $0.14. The insider spent around $14,200 to buy those shares.</li>
<li>What's Happening: On May 9, Zomedica reported a year-over-year decease in first-quarter GAAP EPS results and issued worse-than-expected quarterly sales results.</li>
<li>What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.</li>
</ul>
Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38807221/home-depot-paysafe-and-3-stocks-to-watch-heading-into-tuesday">Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday</a>

CERS

ETST

Zomedica And 3 Other Stocks Under $3 Insiders Are Buying

The Dow Jones index closed lower by more than 500 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Retractable Technologies </h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/quote/RVP/analyst-ratings"> acquired a total of 5,410 shares </a> an average price of $1.24. To acquire these shares, it cost around $6,704.</li>
<li>What&rsquo;s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
<h3>Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) Director R Janet Whitmore <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 182,433 shares at </a> at an average price of $0.40. To acquire these shares, it cost around $72,973. The company&rsquo;s President and CEO also bought 7,008 shares.</li>
<li>What&rsquo;s Happening: Nanophase recently announced rights offering to stockholders.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a U.S based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37091789/top-3-tech-stocks-which-could-rescue-your-portfolio-this-quarter"> Top 3 Tech Stocks Which Could Rescue Your Portfolio This Quarter </a>
<h3>Power Solutions International </h3>
<ul>
<li>The Trade: Power Solutions International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psix#NASDAQ">PSIX</a>) 10% owner Neil Gagnon <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 875 shares </a> at an average price of $1.99. The insider spent around $1,743 to buy those shares.</li>
<li>What&rsquo;s Happening: Power Solutions International, during December, extends its $50 million shareholder loan agreement with Weichai America.</li>
<li>What Power Solutions International Does: Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that primarily run on nondiesel fuels, including natural gas, propane, and gasoline.</li>
</ul>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

PSIX

Retractable Technologies And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed higher by more than 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Lumen Technologies </h3>
<ul>
<li>The Trade: Lumen Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lumn#NYSE">LUMN</a>) Director James Fowler <a href="https://www.benzinga.com/quote/LUMN/analyst-ratings"> acquired a total of 30,000 shares </a> an average price of $1.50. To acquire these shares, it cost around $45,000.</li>
<li>What&rsquo;s Happening: Lumen Technologies reported better-than-expected fourth-quarter financial results.</li>
<li>What Lumen Technologies Does: With 450,000 route miles of fiber, Lumen Technologies is one of the United States&#39; largest telecommunications carriers serving global enterprises.</li>
</ul>
<h3>Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) 10% owner Bradford T Whitmore <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 3,824,864 shares at </a> at an average price of $0.40. To acquire these shares, it cost around $1,529,946.</li>
<li>What&rsquo;s Happening: Nanophase recently announced rights offering to stockholders.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a U.S based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37062571/jim-cramer-says-this-construction-giant-is-so-good-and-goes-higher"> Jim Cramer Says This Construction Giant Is &#39;So Good&#39; And &#39;Goes Higher&#39; </a>
<h3>Sunshine Biopharma </h3>
<ul>
<li>The Trade: Sunshine Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbfm#NASDAQ">SBFM</a>) CEO Steve N. Slilaty <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $0.10. The insider spent around $2,000 to buy those shares.</li>
<li>What&rsquo;s Happening: Sunshine Biopharma posted a narrower-than-expected quarterly loss.</li>
<li>What Sunshine Biopharma Does: Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs.</li>
</ul>

Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Small Cap

LUMN

SBFM

Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Nanophase Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $7.96 million in sales this quarter. This is a 17.78 percent decrease over sales of $9.68 million the same period last year.

Nanophase Technologies Q3 2023 Gaap EPS $(0.03) Down From $(0.02) YoY, Sales $7.96M Down From $9.68M YoY

The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>1847 Holdings </h3>
<ul>
<li>The Trade: 1847 Holdings LLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/efsh#NYSE">EFSH</a>) Chairman and CEO Ellery Roberts <a href="https://www.benzinga.com/quote/MTTR/analyst-ratings"> acquired a total of 75,000 shares </a> an average price of $0.13. To acquire these shares, it cost around $9,475.</li>
<li>What&rsquo;s Happening: 1847 Holdings reported a year-over-year decrease in second-quarter EPS results.</li>
<li>What 1847 Holdings Does: 1847 Holdings LLC is a diversified holding company. It operates in three segments: Retail and appliances, Construction, and Automotive Supplies.</li>
</ul>
<h3>Nanophase Technologies </h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) 10% owner Bradford T Whitmore <a href="https://www.benzinga.com/quote/SWIM/analyst-ratings"> acquired a total of 85,847 shares </a> at an average price of $0.92. The insider spent around $78,899.</li>
<li>What&rsquo;s Happening: Nanophase Technologies reported an increase in second-quarter sales.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a U.S based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3>Kingstone Companies</h3>
<ul>
<li>The Trade: Kingstone Companies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kins#NASDAQ">KINS</a>) Chief Operating Officer Meryl S Golden <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 3,072 shares </a> at an average price of $1.70. To acquire these shares, it cost around $5,221.</li>
<li>What&rsquo;s Happening: Kingstone Companies posted a wider-than-expected quarterly loss.</li>
<li>What Kingstone Companies Does: Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/08/34003747/top-5-tech-stocks-that-are-set-to-fly-this-month"> Top 5 Tech Stocks That Are Set To Fly This Month </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
<h3>Biodesix</h3>
<ul>
<li>The Trade: Biodesix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdsx#NASDAQ">BDSX</a>) Director Jack Schuler <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 128,363 shares </a> at an average price of $1.69. The insider spent $216,510 to buy those shares.</li>
<li>What&rsquo;s Happening: Biodesix posted better-than-expected quarterly results.</li>
<li>What Biodesix Does: Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease.</li>
</ul>

BDSX

EFSH

KINS

Kingstone Companies And 3 Other Stocks Under $2 Insiders Are Buying

Nanophase Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>) reported quarterly earnings of $0.01 per share. The company reported $11.87 million in sales this quarter. This is a 5.79 percent increase over sales of $11.22 million the same period last year.

Nanophase Technologies Q2 EPS $0.01, Sales $11.87M Up From $11.22M YoY

Kevin Cureton, Chief Operating Officer at Nanophase Technologies (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NANX#OTC">NANX</a>), reported a large insider buy on June 6, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000883107/000120919123034678//Archives/edgar/data/883107/000120919123034678/0001209191-23-034678-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Cureton purchased 50,000 shares of Nanophase Technologies. The total transaction amounted to $55,391. 
Nanophase Technologies shares are trading up 1.37% at $1.29 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000883107">Check Out The Full List Of Nanophase Technologies's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

55K Reasons To Be Bullish On Nanophase Technologies Stock

The Dow Jones closed lower by around 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Lexicon Pharmaceuticals </h3>
<ul>
<li>The Trade: Lexicon Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lxrx#NASDAQ">LXRX</a>) 10% owner Invus Advisors Llc <a href="https://www.benzinga.com/quote/LXRX/analyst-ratings"> acquired a total 27,775,050 shares </a> an average price of $2.60. To acquire these shares, it cost around $72.22 million.</li>
<li>What&rsquo;s Happening: Lexicon Pharmaceuticals announced pricing of a $125 million public offering and concurrent private placement.</li>
<li>What Lexicon Pharmaceuticals Does: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.</li>
</ul>
<h3>Heliogen </h3>
<ul>
<li>The Trade: Heliogen, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlgn#NYSE">HLGN</a>) 10% owner Patrick Soonshiong <a href="https://www.benzinga.com/quote/SBIG/analyst-ratings"> acquired a total of 180,012 shares </a> at an average price of $0.25. The insider spent around $44.16 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: Heliogen posted a narrower-than-expected quarterly loss.</li>
<li>What Heliogen Does: Heliogen Inc is a concentrated solar energy system that is being developed to unlock the power of sunlight to replace fossil fuels.</li>
</ul>
<h3>ImmunityBio</h3>
<ul>
<li>The Trade: ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) Director Michael Blaszyk <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 71,915 shares </a> at an average price of $2.75. To acquire these shares, it cost around $198.02 thousand. The company&rsquo;s other Directors also purchased the company&rsquo;s shares.</li>
<li>What&rsquo;s Happening: ImmunityBio announced it received a complete response letter from the FDA on May 9th regarding its BLA for Anktiva in combination with Bacillus Calmette-Gu&eacute;rin.</li>
<li>What ImmunityBio Does: ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/23/06/32714243/top-5-financial-stocks-that-may-implode-in-q2"> Top 5 Financial Stocks That May Implode In Q2 </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h3>Nanophase Technologies </h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) Chief Operating Officer Kevin Cureton <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 50,000 shares </a> at an average price of $1.11. The insider spent $55.39 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: The company&rsquo;s revenue for the first quarter was $9.5 million, representing a 16% year-over-year increase.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a U.S based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>

HLGN

IBRX

LXRX

Over $72M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h2>BioCardia </h2>
<ul>
<li>The Trade: BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) 10% owner Frost Gamma Investments Trust <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 595,238 shares </a> at an average price of $1.68. To acquire these shares, it cost around $1 million.</li>
<li>What&rsquo;s Happening: BioCardia announced a $3.6 million private placement of common stock.</li>
<li>What BioCardia Does: BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs.</li>
</ul>
<h2>Nanophase Technologies </h2>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) Director R. Janet Whitmore <a href="https://www.benzinga.com/quote/NPCE/analyst-ratings"> acquired a total of 10,788 shares </a> at an average price of $1.10. The insider spent around $11.91 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: The company delivered $9.7 million in Q3 revenue.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a US-based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/22/12/30156596/why-fear-level-among-us-investors-is-increasing"> Why Fear Level Among US Investors Is Increasing </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<h2>Corvus Pharmaceuticals</h2>
<ul>
<li>The Trade: Corvus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crvs#NASDAQ">CRVS</a>) 10% owner William Benton Jones <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 20,000 shares </a> at an average price of $0.79. To acquire these shares, it cost around $15.8 thousand.</li>
<li>What&rsquo;s Happening: Corvus Pharmaceuticals recently presented updated data from CPI-818 Phase 1/1b clinical trial at the 64th American Society of Hematology Annual Meeting &amp; Exposition.</li>
<li>What Corvus Pharmaceuticals Does: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.</li>
</ul>
<h2>
AquaBounty Technologies </h2>
<ul>
<li>The Trade: AquaBounty Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqb#NASDAQ">AQB</a>) Director Erin Sharp <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 131,500 shares </a> at an average price of $0.77. The insider spent $101.19 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: The company, last month, reported downbeat quarterly sales.</li>
<li>What AquaBounty Technologies Does: AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology for improving its productivity and sustainability.</li>
</ul>

BCDA

CRVS

$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h2>Intellicheck </h2>
<ul>
<li>The Trade: Intellicheck, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idn#NASDAQ">IDN</a>) President Garrett Gafke <a href="https://www.benzinga.com/sec/insider-trades/"> bought a total of 2,000 shares </a> at an average price of $2.01. To acquire these shares, it cost around $4.02 thousand.</li>
<li>What&rsquo;s Happening: The company&rsquo;s stock dipped around 43% over the past six months.</li>
<li>What Intellicheck Does: Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification.</li>
</ul>
<h2>Corvus Pharmaceuticals </h2>
<ul>
<li>The Trade: Corvus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crvs#NASDAQ">CRVS</a>) CFO Leiv Lea <a href="https://www.benzinga.com/quote/NPCE/analyst-ratings"> acquired a total of 34,000 shares </a> at an average price of $0.75. The insider spent around $25.64 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: Corvus Pharmaceuticals recently presented updated data from CPI-818 Phase 1/1b clinical trial at the 64th American Society of Hematology Annual Meeting &amp; Exposition.</li>
<li>What Corvus Pharmaceuticals Does: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system.</li>
</ul>
<a href="https://www.benzinga.com/news/earnings/22/12/30105887/volatility-in-markets-increases-sharply-amid-recession-concerns">Volatility In Markets Increases Sharply Amid Recession Concerns</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>.
<h3>Nanophase Technologies</h3>
<ul>
<li>The Trade: Nanophase Technologies Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nanx#OTC">NANX</a>) 10% owner Bradford T Whitmore <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 300,488 shares </a> at an average price of $1.10. To acquire these shares, it cost around $330.6 thousand.</li>
<li>What&rsquo;s Happening: The company recently delivered $9.7 million in Q3 revenue.</li>
<li>What Nanophase Technologies Does: Nanophase Technologies Corp is a US-based company engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.</li>
</ul>
<h3>Getaround </h3>
<ul>
<li>The Trade: Getaround, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/getr#NYSE">GETR</a>) CEO &amp; Chairman of the Board Samir Zaid <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 35,000 shares </a> at an average price of $1.13. The insider spent $39.46 thousand to buy those shares.</li>
<li>What&rsquo;s Happening: Getaround announced closing of business combination with InterPrivate II Acquisition Corp.</li>
<li>What Getaround Does: Getaround Inc operates as a developer of a carsharing platform designed to instantly access and drive cars shared by people.</li>
</ul>

GETR

4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More

Nanophase Technologies (OTC:<a class="ticker" href="/stock/NANX#OTC">NANX</a>) reported quarterly earnings of $0.01 per share. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported $4.34 million in sales this quarter. This is a 31.79 percent increase over sales of $3.29 million the same period last year.

Nanophase Technologies Q2 EPS $0.01 Up From $(0.02) YoY, Sales $4.34M Up From $3.29M YoY

Press Releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nanophase Technologies Corporation (OTC: NANX)

Nanophase Technologies Announces Third Quarter 2024 Financial Release and Conference Call Details

Nanophase Reports Record Third Quarter Revenue and Profit

General

Nanophase Technologies Rebrands as Solésence, Elevating the Future of Skin Health

Solésence Launches New Investor Relations Website

Solésence Wins Best Prestige Finished Formula at the 2025 Cosmetics & Toiletries Allē Awards, Marking Third Consecutive Win

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Solesence, Inc. f/k/a Nanophase Technologies Corporation (OTCQB: NANX) and Encourages Current NANX Shareholders to Contact the Firm

Comments

Solesence

Solesence (NANX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO